Ng Boon Huat, Rozita Am, Adlinda A, Lee Wei Ching, Wan Zamaniah Wi
Clinical Oncology Unit, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia E-mail :
Asian Pac J Cancer Prev. 2015;16(9):3827-33. doi: 10.7314/apjcp.2015.16.9.3827.
Positive para-aortic lymph node (PALN) at diagnosis in cervical cancer patients confers an unfavorable prognosis. This study reviewed the outcomes of extended field radiotherapy (EFRT) and concurrent chemotherapy with extended field RT (CCEFRT) in patients with positive PALN at diagnosis.
Medical records of 407 cervical cancer patients between 1st January 2002 to 31st December 2012 were reviewed. Some 32 cases with positive PALN were identified to have received definitive extended field radiotherapy with or without chemotherapy. Treatment outcomes, clinicopathological factors affecting survival and radiotherapy related acute and late effects were analyzed.
Totals of 13 and 19 patients underwent EFRT and CCEFRT respectively during the period of review. The median follow-up was 70 months. The 5-year overall survival (OS) was 40% for patients who underwent CCEFRT as compared to 18% for patients who had EFRT alone, with median survival sof 29 months and 13 months, respectively. The 5-years progression free survival (PFS) for patients who underwent CCEFRT was 32% and 18% for those who had EFRT. Median PFS were 18 months and 12 months, respectively. Overall treatment time (OTT) less than 8 weeks reduced risk of death by 81% (HR=0.19). Acute side effects were documented in 69.7% and 89.5% of patients who underwent EFRT and CCEFRT, respectively. Four patients (12.5%) developed radiotherapy late toxicity and there was no treatment-related death observed.
CCEFRT is associated with higher 5-years OS and median OS compared to EFRT and with tolerable level of acute and late toxicities in selected patients with cervical cancer and PALN metastasis.
宫颈癌患者诊断时主动脉旁淋巴结阳性预后不良。本研究回顾了诊断时主动脉旁淋巴结阳性患者的扩大野放疗(EFRT)及扩大野放疗同步化疗(CCEFRT)的疗效。
回顾了2002年1月1日至2012年12月31日期间407例宫颈癌患者的病历。约32例主动脉旁淋巴结阳性患者接受了单纯或联合化疗的根治性扩大野放疗。分析了治疗效果、影响生存的临床病理因素以及放疗相关的急性和晚期反应。
在回顾期间,分别有13例和19例患者接受了EFRT和CCEFRT。中位随访时间为70个月。接受CCEFRT的患者5年总生存率(OS)为40%,而单纯接受EFRT的患者为18%,中位生存期分别为29个月和13个月。接受CCEFRT的患者5年无进展生存率(PFS)为32%,接受EFRT的患者为18%。中位PFS分别为18个月和12个月。总治疗时间(OTT)少于8周可使死亡风险降低81%(HR=0.19)。接受EFRT和CCEFRT的患者急性副作用发生率分别为69.7%和89.5%。4例患者(12.5%)出现放疗晚期毒性反应,未观察到与治疗相关的死亡。
与EFRT相比,CCEFRT与更高的5年OS和中位OS相关,且在部分伴有主动脉旁淋巴结转移的宫颈癌患者中,急性和晚期毒性反应处于可耐受水平。